Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on trackAvidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-braxReported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nas ...

Avidity Biosciences, Inc. (RNA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ETSAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the com ...

The company's most promising pipeline program can continue unabated. Clinical-stage biotech Avidity Biosciences (RNA 0.53%) had some good news to report toward the end of this week, and investors rewarded it by piling into the company's stock. By the close of trading Friday, said equity had risen almost 12% in value across the week, according to data compiled by S&P Global Market Intelligence. Partial clinical hold released On Thursday, Avidity announced that the U.S. Food and Drug Administration (FDA) has ...

Goldman Sachs has initiated coverage on Avidity Biosciences Inc RNA based on multi-blockbuster, first-tomarket commercial opportunities for its investigational candidates. Avidity Biosciences is a clinical-stage biotechnology company that develops RNA therapeutics (antibody oligonucleotide conjugates) for muscular dystrophies. The company's lead asset, del-desiran (AOC 1001), is currently in the Phase 3 HARBOR trial in patients with myotonic dystrophy type 1 (DM1). The company's pipeline includes Del-brax i ...

SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences: Wells Fargo 2024 Healthcare Conference on September 4 at 5:00 a.m. PT / 8:00 a.m. ET Cantor Global Healthcare Conference on September 17 at 6:45 a.m. PT / 9:45 a.m. ET A live webcast of both ev ...

SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock, including 1,098,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $41.00 per sh ...

Avidity Biosciences Today RNA Avidity Biosciences $44.98 -0.51 (-1.12%) 52-Week Range $4.82 ▼ $48.80 Price Target $54.83 Add to Watchlist Avidity Biosciences NASDAQ: RNA is a biopharmaceutical stock focusing on RNA therapeutics. The company's stock is up around 400% so far in 2024. However, even with this massive appreciation, Wall Street analysts still see a solid upside in the stock. Based on recent analyst changes, the average price target is $62, implying an upside of 39%. Get Sarepta Therapeutics alert ...

SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. In addition, Avidity intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of sh ...

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 14.47%. A quarter ago, it was expected that this company would post a loss of $0.81 per share when it actually produced a loss of $0.79, delivering a surprise of 2.47%. Over the last four quarters, the company ha ...